Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel versus docetaxel rechallenge in metastatic castration-resistant prostate cancer after prior early docetaxel
2012-003835-40Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Nov 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Cabazitaxel with Docetaxel rechallenge (2 arms). Primary endpoint: Clinical progression-free survival. Started Nov 2012; status: completed.
02
Drugs
cabazitaxeldocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2012-003835-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003835-40.